A detailed history of Ensign Peak Advisors, Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 39,137 shares of NVCR stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,137
Previous 39,137 -0.0%
Holding current value
$1.21 Million
Previous $670,000 8.81%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.83 - $24.05 $28,392 - $57,720
2,400 Added 6.53%
39,137 $670,000
Q1 2024

May 14, 2024

SELL
$12.42 - $17.29 $74,867 - $104,224
-6,028 Reduced 14.1%
36,737 $574,000
Q4 2023

Feb 14, 2024

SELL
$11.13 - $15.78 $151,701 - $215,081
-13,630 Reduced 24.17%
42,765 $638,000
Q3 2023

Nov 13, 2023

BUY
$16.15 - $42.35 $349,243 - $915,818
21,625 Added 62.19%
56,395 $910,000
Q2 2023

Aug 14, 2023

BUY
$40.29 - $82.51 $212,731 - $435,652
5,280 Added 17.9%
34,770 $1.44 Million
Q1 2023

May 15, 2023

BUY
$56.44 - $118.81 $36,686 - $77,226
650 Added 2.25%
29,490 $1.77 Million
Q4 2022

Feb 13, 2023

BUY
$63.98 - $85.37 $268,716 - $358,554
4,200 Added 17.05%
28,840 $2.12 Million
Q1 2022

May 16, 2022

SELL
$60.15 - $84.52 $422,854 - $594,175
-7,030 Reduced 22.2%
24,640 $2.04 Million
Q4 2021

Feb 11, 2022

BUY
$75.08 - $121.99 $1.82 Million - $2.96 Million
24,305 Added 330.01%
31,670 $2.38 Million
Q3 2021

Nov 12, 2021

BUY
$116.17 - $194.55 $157,410 - $263,615
1,355 Added 22.55%
7,365 $856,000
Q2 2021

Aug 13, 2021

BUY
$130.4 - $225.58 $783,704 - $1.36 Million
6,010 New
6,010 $1.33 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.23B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.